# Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension

> **NCT00996281** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 837 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Azilsartan medoxomil and chlorthalidone
- **DRUG:** Olmesartan medoxomil and hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00996281
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 837 (ACTUAL)
- **Last updated:** 2012-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996281, "Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00996281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*